Company - Micropos Medical

Micropos medical

Our vision is to play an important role in modern prostate cancer treatment

Enhancing radiotherapy cancer treatment

Micropos Medical is a Swedish medical device company that develops, manufactures, and sells technology enabling enhanced radiotherapy cancer treatment. Our product system, the Raypilot® System, generates high precision as well as high efficiency through real-time tumour tracking in radiation treatment of prostate cancer. Using The Raypilot System, clinics can treat their patients with accuracy and reduced risk of damaging healthy tissue surrounding the tumour.

Short facts

Offering technology enabling enhanced accuracy in radiotherapy prostate cancer treatment
Providing clinics with the Raypilot system that supports the use of SBRT (a shorter and more effective treatment)
minimizes the risk of injuring healthy tissue, and optimizes the workflow
Founded 2003 in Gothenburg, Sweden
Sales in 10 countries in Europe and in the USA
CE Marked and FDA 510(k) approved
More than 270 patients treated
Head office including R&D located in Gothenburg, Sweden
Production performed in Sweden and Germany
3,3 million SEK in revenue 2021
Ove Mattsson is Chairman of the board
Listed on Spotlight Stock Market under the stock ticker MPOS since 2009

More about the company

Micropos Medical was founded within the Swedish business incubator Chalmers Innovation in 2003. It originated from an international team of four oncology professors with extensive knowledge of radiation therapy and a firm belief in real-time tumour tracking. The first patent applications were registered in 2004.

Since then, the company has purposefully and tirelessly developed, marketed, and certified Raypilot – a positioning system that continuously localizes the prostate during radiation therapy. All along, close cooperation with a few high performing radiation clinics has strengthened the product development. Theses reference clinics also perform scientific studies regarding the system and are keen to share their experiences of the system to other potential customers.

As a company we learn a lot through an ongoing dialogue with our users. Simplifying is always on the agenda. Our aim is to offer the users a safe and easy to use-equipment, even though the technology behind it is extremely complex. The introduction of the Raypilot Hypocath catheter in 2018 implied a smoother workflow as well as a new generation of the system and, with the approval of the CE marking in 2020, a commercial breakthrough.

The head office including the research and development department is, since the start, located in Gothenburg, Sweden. Internal personnel resources are scarce but very well qualified and completed by consultant experts within various fields. Subcontractors are mainly found in the Gothenburg region; one is in northern Germany.

Prostate cancer is a global challenge. Micropos Medical has had an international approach from the very beginning, starting with sales in Europe. Well-chosen distributors assist the company in sales as well as in advancing knowledge about organ movement and the importance of precision in radiation therapy. The FDA approval in 2021 regarding marketing and sales in the USA opened a new promising phase in the development of the company.

Financial information

For more information about the stock and Investor information, please visit our Investor page

LEARN MORE

Board & CEO

Ove Mattsson
Chairman of the Board since 2019
Born 1940

B. Sc., Agronomy
Associate Professor, Organic chemistry.

Other assignments:
Board member of MW Collection AB, Board member and CEO of Näset Rådmansö AB.

Previous assignments:
CEO of Casco Nobel and Nobel Industries, Chairman of the Board of Biotage AB, MacGregor AB and Aromatic AB, Board member of Akzo Nobel AB and Ecoclean AB.

Shareholding:
43.498.628 shares via endowment insurances and 120 000 warrants.

Thomas Lindström
CEO of Micropos Medical since 2020
Born 1966

DIHM, Business, Economy, and Marketing, MiL Institute, International management.

Previous assignments and experiences:
CEO of Maquet Getinge Group, Senior Consultant at Green Clinical System Nordic AB, Sales Director and International Sales Manager at Siemens Healthineers.
More than 25 years within medical technology business and extensive experience in leading organizations in change and market introductions.

Shareholding:
1 135 322 shares and 415 961 warrants.

Olof Sandén
Member of the Board since 2019
Born 1962

M. Sc., Mechanical engineering, M.Sc., Business administation.

Other assignments:
Partner of Transearch Sweden, Chairman of the Board of ScandiDos AB, ContextVision AB and Inify Laboratories AB, Board member of Unisport OY.

Previous assignments:
Trade Commissionaire at Business Sweden in Germany, Global Head of Marketing and Executive VP EMEA & Latin America at Elekta, CEO and deputy CEO at RISE.

Shareholding:
166 375 shares (own and through companies), 120 000 warrants.

Tim Thurn
Member of the Board since 2023
Born 1981

German Electrical Engineer, studied at the University of Applied Sciences in Hamburg. MBA degree from the Technical University of Munich.

Other assignments:
Chief Commercial Officer at Oehm & Rehbein in Rostock, Germany.

Previous assignments:
CEO of C-RAD AB (publ.) in Uppsala since 2013. Product manager and later as a sales manager at LAP GmbH, focusing on their patient positioning products.

Shareholding:
Holds no shares or warrants.

Lena Westergren
Member of the Board since 2023
Born 1979

Master of Science in Industrial Engineering, Royal Institute of Technology (KTH).

Other assignments:
CEO and responsible for logistics and financial management in an elite horse sports company. Board Member at Apelsinhöjden Holding AB. Board member in a sub-project under ALM Equity AB.

Previous assignments:
Project Manager in Business Development at Casco Adhesives (Akzo Nobel). Product Manager at L’Oréal Luxury Division.

Shareholding:
5 217 334 shares.